19 results about "Sialidase" patented technology

In a method for treating cancer by desialylation of sialylated glycans expressed on the surface of cancer cells, the present invention provides a method for extending the serum half-life of the active ingredient, sialidase, and enhancing the therapeutic effect of said sialidase. [Solution] A pharmaceutical composition is provided that contains sialidase which, when administered to a subject, conjugates to a serum half-life enhancing factor that increases the serum half-life of sialidase.

To provide a detection reagent hardly causing noise due to generation of nonspecific fluorescence, and capable of detecting sialidase with higher accuracy.SOLUTION: The present invention relates to a compound represented by formula (I) or a salt thereof, or a solvate thereof. In the formula (I), R1 represents a halogen atom, and R2 represents an alkyl group having 5 to 11 carbon atoms or a hydrocarbyl group having 5 to 11 carbon atoms and having one or more unsaturated bonds. ] SELECTED DRAWING: None

Described are processes for the production of a composition comprising (2R, 3R, 4R, 5S)-3, 4, 5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of: a) providing plant material from a botanical source comprising plant of the family Cucurbitaceae; b) fractionating said plant material to produce an extract enriched in idoBR1 c) assaying said extract for: i) inhibitory activity against sialidase or TNF-alpha or ii) IL-10 stimulatory activity; and d) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.

The present invention relates generally to recombinant sialidases, methods and compositions for extending the serum half-life of the recombinant sialidases, and their use in the treatment of sialic acid-related disorders.

To provide a recombinant human sialidase and a recombinant sialidase fusion protein useful for treating cancer.SOLUTION: The present invention relates generally to recombinant human sialidases and recombinant sialidase fusion proteins, wherein the sialidase optionally includes one or more mutations, e.g., a substitution, deletion or addition of at least one amino acid, as compared to a wild-type human sialidase. The present invention also provides antibody conjugates comprising a sialidase and an antibody or portion thereof. The invention further relates to methods of using sialidase fusion proteins or antibody conjugates to treat cancer.SELECTED DRAWING: None

The present disclosure provides modified immune cells or precursors thereof (e.g. modified T cells) comprising a chimeric cell surface sialidase or a variant sialidase precursor protein. Compositions and methods of treatment are also provided.

The invention discloses a UMOD antibody, a sialidase NEU3 fusion protein and application thereof.The UMOD antibody is invented firstly, VL-CL and VH-CH1 nucleotide sequences of a Fab fragment of the UMOD antibody and a nucleotide sequence of a sialidase NEU3 functional area peptide fragment are used for constructing a recombinant vector, then the recombinant vector is expressed and purified to obtain the fusion protein, and the fusion protein is directly administrated through a bladder to treat bladder cancer. The sialidase NEU3 can identify the UMOD antigen, can play a role in degrading sialic acid of the sialidase NEU3, can significantly inhibit the growth of bladder cancer, and has the advantages of simple operation and good treatment effect.

The invention belongs to the technical field of biology, and particularly relates to a method for detecting and enriching glycosylated RNA (Ribonucleic Acid) based on in-vitro enzyme chemical labeling of alpha-2, 3, alpha-2, 6 type sialyltransferase. According to the application, sialidase is firstly used for digesting sialic acid at the tail end of a naturally generated glycoRNA sugar chain, and sialidase digestion is not needed for an RNA sample which does not have sialic acid at the tail end of the glycoRNA sugar chain but has potential sialic acid modification sites; sialic acid with a labeled group is transferred to a potential sialic acid modification site at the tail end of a glycoRNA carbohydrate chain by using alpha-2, 3, alpha-2, 6 type sialyltransferase, such as PmST1, PmST3, Ph2, 3siat and Pd26ST, so that glycoRNA with a detectable group can be directly obtained, or the detectable group is further introduced through subsequent reaction, so that subsequent signal detection or enrichment can be carried out; the RNA part can be further sequenced, and the glycosyl part can be further subjected to mass spectrum identification. The application provides a very efficient, simple and convenient detection means for detection and enrichment of sialylated glycoRNA, has the characteristics of high specificity and high sensitivity, and has a wide application prospect.

Disclosed are a method of preparing a saccharide that contains a 3-fluoro-sialic acid and a method of bonding it to a homogeneous antibody. Also within the scope of this invention are compounds each containing a 3-fluoro-sialic acid, monoclonal antibodies bonded to α2,6-linked 3-fluoro-sialoside terminated N-glycans, and treatment of cancer with such monoclonal antibodies.

This invention belongs to the field of tumor vaccine technology, specifically relating to a desialylated tumor cell-derived vesicle, its preparation method, and its application. The preparation method of desialylated tumor cell-derived vesicles is as follows: Sialidase solution is co-incubated with tumor cells for desialylation treatment to obtain tumor cells free of sialic acid; the tumor cells free of sialic acid are extruded, filtered, centrifuged, and the precipitate is collected to obtain desialylated tumor cell-derived vesicles. This invention can obtain a large amount of sialylase at low cost and high efficiency, with an enzyme activity as high as 21 U / mL, and efficiently removes sialic acid from the surface of tumor cells with high sialic acid expression. The prepared vesicles are all around 130 nm in size and have a distinct bilayer structure. The desialylated tumor cell-derived vesicles exhibit good immunological activity. The tumor vaccine prepared using this invention can significantly inhibit tumor growth and has good anti-tumor activity and safety.

The invention discloses a DNA cube-sialidase conjugate as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The main body of the conjugate is a DNA cube, and is formed by DNA single chains of an AB chain, an AE chain, an AD chain, an AC chain, an a chain, a chain b and an x chain which are respectively shown as SEQ ID NO: 1-7 through base complementary pairing assembly; the 5'end of the chain a or the chain b is complementary with a DNA cube support chain to form double chains, the 3 'end is free in a single-chain form, so that four nonadjacent vertexes of the DNA cube respectively extend to form a single-chain DNA section, and the 3' end of each single-chain DNA section is connected with sialidase. Sialic acid on the cell surface is subjected to targeted degradation through the DNA cube-sialidase conjugate, and the DNA cube-sialidase conjugate can be used for targeted degradation of sugar immune checkpoints on the surface of tumor cells, has high targeting property and action efficiency, and is expected to be used for enhancing immunotherapy.

The invention relates to the field of biological detection, in particular to a detection reagent and application thereof. The invention provides a detection reagent which comprises the following components: 10 to 200 mM of a buffer solution, 5 to 20 g / L of polyvinylpyrrolidone K30 or K90, 0.5 to 10 g / L of 5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid sodium salt or 5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid, and 0.1 to 5 g / L of diazonium salt. According to the sialidase detection test paper provided by the invention, after a sample is dropwise added into the test paper, direct color development can be realized, an independently packaged joint detection color development solution is not needed, and the test paper is simple and convenient to operate and easy to popularize.

To provide a method of preparing a saccharide that contains 3-fluoro-sialic acid and a method of bonding it to a homogeneous antibody.SOLUTION: Provided is a monoclonal antibody having a saccharide containing 3-fluoro-sialic acid, wherein the saccharide containing 3-fluoro-sialic acid is prepared by the steps of: conducting a glycosylation reaction by reacting 3-hydroxy-sialic acid with a saccharide to form an α2,6-linked 3-hydroxy-sialoside; and conducting a fluorination reaction by reacting the α2,6-linked 3-hydroxy-sialoside with a fluorinating agent to form the saccharide containing 3-fluoro-sialic acid.SELECTED DRAWING: Figure 1A

The invention provides a quality control product for detecting vaginal secretion and a preparation method of the quality control product. The quality control product comprises a negative quality control product and a positive quality control product; the positive quality control product comprises 20-200 mM of a second basic buffer solution, 1-5% of a second enzyme protective agent, 0-0.04% of lactic acid, 0-0.005% of hydrogen peroxide, 0.01-0.1 U / mL of a second leukocyte esterase item, 0.02-0.1 U / mL of sialidase, 0.05-0.5 U / mL of a second N-acetylglucosaminidase item, 50-200 U / mL of a second oxidase item, 2-40 U / mL of a second coagulase item, 50-200 U / mL of beta-glucuronidase, 5-20 U / mL of proline aminopeptidase, 1-5 U / mL of a second alkaline phosphatase item and 0.2-0.2. And 1% of bovine serum albumin.

The application provides a canine mycoplasma, a culture method and application thereof. A new canine mycoplasma is isolated, and the canine mycoplasma is named QAU241017.16 and preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 23, 2025, with a preservation number of CGMCC No. 46643. The isolated strain has 8 amino acid site mutations on a sialidase gene, and the animal experiment proves that the virulence is significantly enhanced. The inactivated vaccine prepared from the canine mycoplasma has good immunogenicity and safety, and can effectively stimulate the body to produce antibodies against the canine mycoplasma. The inactivated vaccine prepared based on the strain can induce a neutralizing antibody titer of 1:128. The application can provide a new scheme for the prevention and control of the canine mycoplasma. The canine mycoplasma isolation and culture method provided by the application is lower in cost, more efficient, and can realize rapid proliferation of the mycoplasma, so that a higher viable bacterial titer is achieved. Technical support is provided for the isolation and culture of the canine mycoplasma.

The invention relates generally to recombinant sialidases, methods and compositions for extending the serum half-life of the recombinant sialidases, and use of the same in the treatment of a sialic acid-related disorder.

The invention relates to the field of biomedicine, in particular to a multi-immune checkpoint fusion protein as well as a preparation method and application thereof. The invention discloses a functionalized fusion protein which is composed of two modularized fusion proteins: a first module protein is a targeting module and has the function of a traditional immune checkpoint inhibitor; the second module protein is a sialidase long circulation module and has the function of a sugar immune checkpoint inhibitor; the two modular proteins can be specifically bound by a spy reaction through spontaneously formed covalent bonds. And under the synergistic effect of multi-immune checkpoint inhibition, the compound has an excellent anti-tumor immunotherapy effect.

Disclosed are methods of preparing 3-fluorosialic acid-containing sugars, and methods of conjugating the same to homogeneous antibodies. Also within the scope of the invention are 3-fluorosialic acid-containing compounds, monoclonal antibodies conjugated to N-glycans terminating in 3-fluorosialic acid glycosides linked in an alpha 2,6 configuration, and methods of using such monoclonal antibodies to treat cancer.

The present invention relates to a method for producing hyaluronidase PH20 or a variant thereof and, more specifically, to a method for producing hyaluronidase PH20 or a variant thereof, and a use thereof, hyaluronidase PH20 having a significantly reduced half-life in blood, while maintaining enzyme activity and thermal stability, due to sialidase treatment.